ReviewMolecular diagnosis & therapy2017
Genetic Counselling for Maternally Inherited Mitochondrial Disorders.
Review in Molecular diagnosis & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 119 citations in OpenAlex.
- Diagnosing Pearson syndrome requires proving a single mtDNA deletion.Journal of medical case reports · 2026Article
- Mitochondrial Genetic Diseases and Ophthalmic Manifestations: Molecular Pathophysiology, Genetics, and Clinical Management.International journal of molecular sciences · 2026Review
- Recurrent Miscarriages and Postpartum Heart Failure Can Be Phenotypic Manifestations of the m.3243A>G Variant.Clinical case reports · 2026Article
- Mitochondrial replacement techniques for treating infertility.Journal of medical ethics · 2026Article
- Autosomal Recessive Alport Syndrome Should Be Diagnosed in an m.3243A>G Carrier Only If a Pathogenic COL4A3 Variant Has Been Detected.Internal medicine (Tokyo, Japan) · 2026Article
- Before PAX1, DKK1, and D-loop variants are held responsible for the Chiari-I malformation, the pathogenicity of each variant must be proven.Croatian medical journal · 2026Article
- Retinopathy and focal segmental glomerulosclerosis are not uncommon phenotypic features in m.3243A>G carriers.International journal of ophthalmology · 2026Article
- Many Factors Determine Phenotypic Heterogeneity in LHON [Letter].International medical case reports journal · 2026Article
- Comments on: "Stroke-Like Episode, Aphasia, and Hearing Loss in MELAS".Journal of clinical neurology (Seoul, Korea) · 2025Article
- Comprehensive basic and clinical studies are needed to improve the treatment and outcome of patients with Kearns-Sayre syndrome.Translational pediatrics · 2025Article
- Diagnosing Kearns-Sayre syndrome requires documentation of the underlying genetic defect.The Pan African medical journal · 2025Article
- The Presence of the mtDNA4977 Deletion Does Not Necessarily Mean That It is Responsible for Major Depression [Letter].Neuropsychiatric disease and treatment · 2025Article
- The m.3243A>G variant affects not only islet, hair, or retinal ganglion cells, but all cells.GMS ophthalmology cases · 2025Article
- Selection promotes age-dependent degeneration of the mitochondrial genome.bioRxiv : the preprint server for biology · 2024Article
- Fetal and obstetrics manifestations of mitochondrial diseases.Journal of translational medicine · 2024Review
- Mechanisms of mitochondrial dysfunction in ovarian aging and potential interventions.Frontiers in endocrinology · 2024Review
- Before Attributing Malnutrition in Melas to Superior Mesenterica Artery Syndrome, all Differentials must be Excluded.European journal of case reports in internal medicine · 2024Article
- Diagnosing Kearns-Sayre syndrome requires clinical and genetic evidence.Journal of family medicine and primary care · 2023Article
- Stroke-like lesions should not be mixed up with ischemic stroke in MELAS with cardioembolic risk.Clinical case reports · 2023Article
- Modeling-based prediction tools for preimplantation genetic testing of mitochondrial DNA diseases: estimating symptomatic thresholds, risk, and chance of success.Journal of assisted reproduction and genetics · 2023Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
The aim of this review was to provide an evidence-based approach to frequently asked questions relating to the risk of transmitting a maternally inherited mitochondrial disorder (MID). We do not address disorders linked with disturbed mitochondrial DNA (mtDNA) maintenance, causing mtDNA depletion or multiple mtDNA deletions, as these are autosomally inherited. The review addresses questions regarding prognosis, recurrence risks and the strategies available to prevent disease transmission. The clinical and genetic complexity of maternally inherited MIDs represent a major challenge for patients, their relatives and health professionals. Since many of the genetic and pathophysiological aspects of MIDs remain unknown, counselling of affected patients and at-risk family members remains difficult. MtDNA mutations are maternally transmitted or, more rarely, they are sporadic, occurring de novo (~25%). Females carrying homoplasmic mtDNA mutations will transmit the mutant species to all of their offspring, who may or may not exhibit a similar phenotype depending on modifying, secondary factors. Females carrying heteroplasmic mtDNA mutations will transmit a variable amount of mutant mtDNA to their offspring, which can result in considerable phenotypic heterogeneity among siblings. The majority of mtDNA rearrangements, such as single large-scale deletions, are sporadic, but there is a small risk of recurrence (~4%) among the offspring of affected women. The range and suitability of reproductive choices for prospective mothers is a complex area of mitochondrial medicine that needs to be managed by experienced healthcare professionals as part of a multidisciplinary team. Genetic counselling is facilitated by the identification of the underlying causative genetic defect. To provide more precise genetic counselling, further research is needed to clarify the secondary factors that account for the variable penetrance and the often marked differential expressivity of pathogenic mtDNA mutations both within and between families.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.